DE60127098T2 - Inhibitoren der mucin-synthese - Google Patents

Inhibitoren der mucin-synthese Download PDF

Info

Publication number
DE60127098T2
DE60127098T2 DE60127098T DE60127098T DE60127098T2 DE 60127098 T2 DE60127098 T2 DE 60127098T2 DE 60127098 T DE60127098 T DE 60127098T DE 60127098 T DE60127098 T DE 60127098T DE 60127098 T2 DE60127098 T2 DE 60127098T2
Authority
DE
Germany
Prior art keywords
use according
composition
mucin
cells
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60127098T
Other languages
German (de)
English (en)
Other versions
DE60127098D1 (de
Inventor
Yuhong Plymouth Meeting ZHOU
Roy C. Plymouth Meeting LEVITT
Nicholas C. Plymouth Meeting NICOLAIDES
Steve Plymouth Meeting JONES
Mike Plymouth Meeting MCLANE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genaera Corp
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaera Corp filed Critical Genaera Corp
Publication of DE60127098D1 publication Critical patent/DE60127098D1/de
Application granted granted Critical
Publication of DE60127098T2 publication Critical patent/DE60127098T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE60127098T 2000-01-31 2001-01-31 Inhibitoren der mucin-synthese Expired - Fee Related DE60127098T2 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US17912700P 2000-01-31 2000-01-31
US179127P 2000-01-31
US19311100P 2000-03-30 2000-03-30
US193111P 2000-03-30
US23078300P 2000-09-07 2000-09-07
US230783P 2000-09-07
US24213400P 2000-10-23 2000-10-23
US242134P 2000-10-23
US25205200P 2000-11-20 2000-11-20
US252052P 2000-11-20
PCT/US2001/003078 WO2001054685A1 (en) 2000-01-31 2001-01-31 Mucin synthesis inhibitors

Publications (2)

Publication Number Publication Date
DE60127098D1 DE60127098D1 (de) 2007-04-19
DE60127098T2 true DE60127098T2 (de) 2007-11-29

Family

ID=27539006

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60127098T Expired - Fee Related DE60127098T2 (de) 2000-01-31 2001-01-31 Inhibitoren der mucin-synthese

Country Status (13)

Country Link
US (2) US6737427B2 (https=)
EP (1) EP1255544B1 (https=)
JP (1) JP2004507444A (https=)
AR (1) AR042578A1 (https=)
AT (1) ATE355836T1 (https=)
AU (2) AU2001234671B2 (https=)
CA (1) CA2398642A1 (https=)
CY (1) CY1106643T1 (https=)
DE (1) DE60127098T2 (https=)
DK (1) DK1255544T3 (https=)
ES (1) ES2282235T3 (https=)
PT (1) PT1255544E (https=)
WO (1) WO2001054685A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345051B2 (en) * 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
US20020147216A1 (en) * 2000-01-31 2002-10-10 Yuhong Zhou Mucin synthesis inhibitors
ES2282235T3 (es) * 2000-01-31 2007-10-16 Genaera Corporation Inhibidores de la sintesis de la mucina.
US8474460B2 (en) 2000-03-04 2013-07-02 Pulmonx Corporation Implanted bronchial isolation devices and methods
US6904909B2 (en) 2000-03-04 2005-06-14 Emphasys Medical, Inc. Methods and devices for use in performing pulmonary procedures
US6679264B1 (en) 2000-03-04 2004-01-20 Emphasys Medical, Inc. Methods and devices for use in performing pulmonary procedures
US20030059434A1 (en) * 2000-08-09 2003-03-27 Andrew Grupe Methods and compositions for treating gastrointestinal tract mucin production associated disease conditions
US7011094B2 (en) 2001-03-02 2006-03-14 Emphasys Medical, Inc. Bronchial flow control devices and methods of use
US20030050648A1 (en) 2001-09-11 2003-03-13 Spiration, Inc. Removable lung reduction devices, systems, and methods
AU2002347900B8 (en) 2001-10-11 2006-01-12 Emphasys Medical, Inc. Bronchial flow control devices and methods of use
US6592594B2 (en) 2001-10-25 2003-07-15 Spiration, Inc. Bronchial obstruction device deployment system and method
US6818446B2 (en) 2001-11-21 2004-11-16 The Regents Of The University Of California Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression
US6929637B2 (en) 2002-02-21 2005-08-16 Spiration, Inc. Device and method for intra-bronchial provision of a therapeutic agent
WO2003075796A2 (en) 2002-03-08 2003-09-18 Emphasys Medical, Inc. Methods and devices for inducing collapse in lung regions fed by collateral pathways
US20030216769A1 (en) 2002-05-17 2003-11-20 Dillard David H. Removable anchored lung volume reduction devices and methods
US20030181922A1 (en) 2002-03-20 2003-09-25 Spiration, Inc. Removable anchored lung volume reduction devices and methods
US20040059263A1 (en) 2002-09-24 2004-03-25 Spiration, Inc. Device and method for measuring the diameter of an air passageway
DE60323502D1 (de) 2002-07-26 2008-10-23 Emphasys Medical Inc Bronchiale durchflussvorrichtung mit einer membranabdichtung
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US7100616B2 (en) 2003-04-08 2006-09-05 Spiration, Inc. Bronchoscopic lung volume reduction method
MXPA05012728A (es) 2003-05-28 2006-02-13 Wyeth Corp Clca-1 soluble y antagonistas para el clca-1.
EP1633734A2 (en) * 2003-06-19 2006-03-15 Genaera Corporation Mucin synthesis inhibitors
US7533671B2 (en) 2003-08-08 2009-05-19 Spiration, Inc. Bronchoscopic repair of air leaks in a lung
JP2008507368A (ja) * 2004-07-22 2008-03-13 デュスカ サイエンティフィック カンパニー 肺疾患を診断、モニタリングおよび治療するための方法
US7771472B2 (en) 2004-11-19 2010-08-10 Pulmonx Corporation Bronchial flow control devices and methods of use
EP1827479A1 (en) * 2004-12-09 2007-09-05 Ingenium Pharmaceuticals AG Methods and agents useful in treating conditions characterized by mucus hyperproduction/ hypersecretion
WO2006075172A2 (en) * 2005-01-13 2006-07-20 University Of Dundee Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2
US8876791B2 (en) 2005-02-25 2014-11-04 Pulmonx Corporation Collateral pathway treatment using agent entrained by aspiration flow current
US7691151B2 (en) 2006-03-31 2010-04-06 Spiration, Inc. Articulable Anchor
AU2007272970C1 (en) 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
EP3669878A1 (en) 2006-08-10 2020-06-24 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
WO2008112141A1 (en) * 2007-03-07 2008-09-18 Northeastern University Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation
US8136230B2 (en) 2007-10-12 2012-03-20 Spiration, Inc. Valve loader method, system, and apparatus
GB0905954D0 (en) * 2009-04-06 2009-05-20 E Therapeutics Plc Treatment of exacerbations of asthma
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
WO2012134965A1 (en) * 2011-03-25 2012-10-04 The Trustees Of Columbia University In The City Of New York Chloride channel and chloride transporter modulators for therapy in smooth muscle diseases
WO2013044267A1 (en) 2011-09-23 2013-03-28 Pulmonx, Inc. Implant loading device and system
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
WO2015182565A1 (ja) * 2014-05-27 2015-12-03 リンク・ジェノミクス株式会社 肺疾患治療剤
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4168313A (en) 1978-02-21 1979-09-18 Sebastian Bago Phthalidyl 2-(3'-trifluoromethyl-anilino)-pyridine-3-carboxylate and its salts
US4515980A (en) * 1983-07-11 1985-05-07 Sterling Drug Inc. Substituted aminobenzoates, their preparation and use
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4666716A (en) * 1984-09-04 1987-05-19 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
DE3682136D1 (de) 1985-07-31 1991-11-28 Hoechst Ag N-substituierte 5-nitroanthranilsaeuren, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen.
DE3608726A1 (de) * 1986-03-15 1987-09-17 Hoechst Ag Verwendung aminosubstituierter benzoesaeuren als heilmittel gegen diarrhoe und arzneimittel auf basis dieser verbindungen
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
US5733748A (en) 1995-06-06 1998-03-31 Human Genome Sciences, Inc. Colon specific genes and proteins
WO1997003659A1 (de) * 1995-07-20 1997-02-06 Uwe Juergens Verwendung eines nicht-steroidalen antiphlogistikums zur topischen und systemischen behandlung der akuten und chronischen polypoiden rhinosinusitis
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
NZ336659A (en) * 1997-01-08 2001-01-26 Upjohn Co Pharmaceutically active pyrimido[4,5-b]indoles
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
CA2290509A1 (en) * 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
AU2674399A (en) * 1998-02-11 1999-08-30 Regents Of The University Of California, The Compositions and methods for the inhibition of muc-5 mucin gene expression
CA2321664C (en) 1998-03-03 2009-06-02 Magainin Pharmaceuticals, Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
JP2002534380A (ja) * 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による喘息の治療
HUP0105092A3 (en) * 1999-01-13 2003-12-29 Warner Lambert Co 1-heterocycle substituted diarylamines and medicaments containing them
CA2349832A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
US6245320B1 (en) * 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
AU7965000A (en) * 1999-09-27 2001-04-30 Jun-Suk Oh Use of analgesics as digestive and medicines for expectorating and transdermal therapeutic system using the same
ES2282235T3 (es) 2000-01-31 2007-10-16 Genaera Corporation Inhibidores de la sintesis de la mucina.
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
US6737427B2 (en) 2004-05-18
AR042578A1 (es) 2005-06-29
JP2004507444A (ja) 2004-03-11
AU2001234671B2 (en) 2006-05-18
DE60127098D1 (de) 2007-04-19
ATE355836T1 (de) 2007-03-15
US20040254096A1 (en) 2004-12-16
ES2282235T3 (es) 2007-10-16
CA2398642A1 (en) 2001-08-02
US7504409B2 (en) 2009-03-17
US20010041685A1 (en) 2001-11-15
CY1106643T1 (el) 2012-01-25
PT1255544E (pt) 2007-06-15
AU3467101A (en) 2001-08-07
EP1255544B1 (en) 2007-03-07
DK1255544T3 (da) 2007-09-17
EP1255544A4 (en) 2005-02-02
WO2001054685A1 (en) 2001-08-02
EP1255544A1 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
DE60127098T2 (de) Inhibitoren der mucin-synthese
AU2001234671A1 (en) Mucin synthesis inhibitors
US7345051B2 (en) Mucin synthesis inhibitors
DE69830582T2 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
DE69916496T2 (de) Zusammensetzung und verfahren
EP2110132B1 (de) Verwendung von Deuteriumoxid als Elastase-Inhibitor
US20020165244A1 (en) Mucin synthesis inhibitors
US20050249675A1 (en) Mucin synthesis inhibitors
DE60120111T2 (de) Verwendung einer emap-ii-rezeptor-antagonisten verbindung zur behandlung pulmonaler hypertension
WO2021228750A1 (de) Kompatible solute zur prävention oder behandlung von sars-cov-2-infektionen
US20020147216A1 (en) Mucin synthesis inhibitors
DE69224795T2 (de) 4Verfahren und Zusammensetzungen zur Vorbeugung, Diagnose und Behandlung seröser Entzündungen und damit verbundener Störungen
Diebel et al. Ethanol impairs intestinal barrier defense by modulation of immunoglobulin A transport
JP2002338493A (ja) ムチン合成インヒビター
DE102017110935A1 (de) Anti-inflammatorische hochreine Oligosaccharide
Apablaza et al. Airway succinate chemosensing induces CFTR-dependent anion secretion and mucus clearance which is impaired in cystic fibrosis
Wang et al. An animal study on the effect of topically administered ambroxol for dry eye
Ramya et al. Effect of anti-inflammatory activity of Hellenia speciosa (L.) and Costus pictus (L.)
AU2002320299A1 (en) Mucin synthesis inhibitors
Mangai EVALUATION OF ANTI–INFLAMMATORY ACTIVITY OF KARAI RASAYANAM, A SIDDHA PEDIATRIC DRUG.
Patel Characterising and Treating a Refined Model of Allergic Airways Disease that mimics the key features of Human Asthma
JP2002338494A (ja) ムチン合成インヒビター

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee